Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although BEZ235 showed satisfactory antitumor activity against various cancer types in a preclinical model, poor tolerability and high adverse events were observed in clinical trials38–41.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to the MAPK pathway, the PI3K/AKT pathway primarily regulates cell survival, metabolism, growth, and drug resistance [10,11].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although BEZ235 showed satisfactory antitumor activity against various cancer types in a preclinical model, poor tolerability and high adverse events were observed in clinical trials38–41.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · cited 1×
“Class 1 PI3K family members that convert phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) thereby activating AKT via two crucial phosphorylation events at threonine 308 catalyzed by phosphoinositide-dependent kinase-1 (PDK1) and at serine 473 catalyzed by mammalian target…”
BackgroundMammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111 · cited 1×
“Activated MEK phosphorylates its only substrate ERK1/2 leading to dimerization, nuclear translocation and induction of target genes [5,6].”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558 · cited 1×
“mTORC1 has been shown to regulate cell growth by controlling mRNA translation initiation and to regulate ribosome biogenesis, autophagy and lipid biosynthesis [34].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Coexisting mutations of the PIK3CA, which occur in about 8%–9% of CRC cases [25,26], have also been implicated in the resistance of KRAS mutated CRC cells to MEK inhibition [27,28].”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · cited 1×
“Genetic anomalies of PI3K pathway components, such as PTEN loss, PI3K amplification/mutation, AKT mutation or RTK activation, result in activation of this pathway leading to tumorigensis [3].”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328 · cited 1×
“RAS and RAF gene mutations have been considered potential markers of sensitivity to MEK inhibition largely due to the constitutive activation of MEK seen in BRAF mutant cancer cells and to a lesser extent in KRAS mutant cells [17,18].”
BackgroundThe insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124 · cited 1×
“Insulin-like growth factor-1 receptor (IGF-1R) is a key activator of these two pro-survival signaling pathways [1].”
BackgroundThe PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878 · cited 1×
“mTOR inhibition has been correlated with activation of MAPK pathway through PI3K’s activation of RAS [42].”
BackgroundPhosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., & Cobb, M. H. (1998) · Cell · doi:10.1016/s0092-8674(00)81189-7 · Cited by 677 · cited 1×
“Activated MEK phosphorylates its only substrate ERK1/2 leading to dimerization, nuclear translocation and induction of target genes [5,6].”
BackgroundRinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645 · cited 1×
“Generally, CI-1040 was well tolerated but failed to show sufficient antitumor activity to warrant further development [10].”
BackgroundEssential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., & Guan, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.119 · Cited by 610 · cited 1×
“mTORC2 on the other hand is involved in cell survival and proliferation through phosphorylation of AKT and protein kinase C [35].”
BackgroundRoock, W. D., Vriendt, V. D., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 603 · cited 6×
“Mutations in the KRAS gene are the most common in CRCs comprising approximately 35%–45% [4].”
BackgroundInfluentialSorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 540 · cited 1×
“Thus, MEK has become a potential target for therapy given that mutation in these kinases has been identified as a negative predictor of benefit from EGFR inhibitor therapy [19–21].”
BackgroundPI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · cited 1×
“In this study, the most frequent drug-related grade >III adverse events were liver transaminase elevations, mucositis and skin rash [52].”
BackgroundLoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401 · cited 1×
“Several selective inhibitors of MEK have entered clinical trial evaluation [7]; however, clinical activity with single MEK inhibitors has been rarely observed [8–10].”
BackgroundDavies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368 · cited 1×
“ERBB receptor activation and upregulation of the ERBB3/PI3K/AKT signaling pathway, which was no longer responsive to MEK inhibition [14].”
BackgroundAKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343 · cited 1×
“AKT upregulation occurs in approximately 60% of CRC cases which renders AKT a potential target for inhibition [48].”
BackgroundPIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331 · cited 1×
“Colorectal cancer patients with PIK3CA and KRAS mutations did not respond to therapy [31].”
BackgroundFrom basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243 · cited 1×
“Several selective inhibitors of MEK have entered clinical trial evaluation [7]; however, clinical activity with single MEK inhibitors has been rarely observed [8–10].”
BackgroundHoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242 · cited 1×
“growth inhibition of BRAF and KRAS mutated cell lines and human xenograft tumor models [40].”
BackgroundPIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations
Nosho, K., Kawasaki, T., Longtine, J. A., Fuchs, C. S., Ohnishi, M., Suemoto, Y., Kirkner, G. J., Zepf, D., Yan, L., & Ogino, S. (2008) · Neoplasia · doi:10.1593/neo.08336 · Cited by 238 · cited 1×
“Coexisting mutations of the PIK3CA, which occur in about 8%–9% of CRC cases [25,26], have also been implicated in the resistance of KRAS mutated CRC cells to MEK inhibition [27,28].”
BackgroundPI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 216
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S. G., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 211 · cited 1×
“Several selective inhibitors of MEK have entered clinical trial evaluation [7]; however, clinical activity with single MEK inhibitors has been rarely observed [8–10].”
BackgroundLittle, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210 · cited 3×
“Tumor cells harboring the BRAF600E mutation have shown similar resistance to MEK1/2 inhibitors “Figure 1” by increasing signaling through the ERK1/2 pathway due to amplification of the oncogene [13,22].”
Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2683 · Cited by 191 · cited 1×
“reported on an analysis of forty different patient-derived murine xenografts of metastatic CRC [44].”
BackgroundHalilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
Balmanno, K., Chell, S. D., Gillings, A. S., Hayat, S., & Cook, S. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24604 · Cited by 143 · cited 1×
“tended to be resistant [30].”
Do, K., Speranza, G., Bishop, R., Khin, S., Rubinstein, L., Kinders, R. J., Datiles, M., Eugeni, M., Lam, M. H., Doyle, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0212-z · Cited by 132 · cited 2×
“These toxicities hindered the possibility of dose escalation to achieve levels needed for clinical activity [54].”
BackgroundComprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Jing, J., Greshock, J., Holbrook, J. D., Gilmartin, A., Zhang, X., McNeil, E., Conway, T., Moy, C., Laquerre, S., Bachman, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0505 · Cited by 121 · cited 2×
“Among RAF/RAS mutant lines, co-occurring PIK3CA/PTEN mutations conferred a cytostatic response instead of a cytotoxic response for colon cancer cells [28].”
BackgroundResistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119 · cited 3×
“Tumor cells harboring the BRAF600E mutation have shown similar resistance to MEK1/2 inhibitors “Figure 1” by increasing signaling through the ERK1/2 pathway due to amplification of the oncogene [13,22].”
BackgroundBennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T.-Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 116 · cited 1×
“Selumetinib showed similar efficacy to capecitabine in terms of the number of patients with a disease progression event and progression-free survival [11].”
BackgroundMartinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92 · cited 1×
“revealed that the selective MEK1/2 inhibitor pimasertib combined with the dual PI3K/mTOR inhibitor BEZ235 or with sorafenib caused significant tumor growth delays and increased survival in mice as compared to single agent treatment thereby suggesting that dual blockade of MAPK and PI3K pathways could overcome intrinsi…”
BackgroundYu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., & Zask, A. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5334 · Cited by 89 · cited 1×
“found that the HCT116 cell line, which harbors mutations in both KRAS and PIK3CA, was resistant to the PI3K inhibitors WAY-266176 and WAY-266175; however, combined therapy with the MEK inhibitors CI-1040 or UO126 led to growth suppression and apoptosis [39].”
BackgroundHolt, S. V., Logie, A., Davies, B. R., Alferez, D., Runswick, S., Fenton, S., Chresta, C. M., Gu, Y., Zhang, J., Wu, Y.-L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1780 · Cited by 86 · cited 1×
“also investigated the efficacy of AZD8055, a potent specific inhibitor of mTORC1 and mTORC2, in combination with selumetinib in human tumor non-small cell lung cancer (NSCLC) and CRC cell-derived xenograft and primary patient explants models [37].”
BackgroundThe synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
Haagensen, E. J., Kyle, S., Beale, G. S., Maxwell, R. J., & Newell, D. R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.70 · Cited by 79 · cited 1×
“found that the pan-PI3K inhibitor GDC-0941 demonstrated greater synergy than the dual PI3K/mTOR inhibitor BEZ235 when combined with the MEK inhibitors selumetinib and PD0325901 in BRAF/PIK3CA-double-mutant HT29 and KRAS/PIK3CA-double-mutant HCT116 CRC cell lines [47].”
BackgroundTentler, J. J., Nallapareddy, S., Tan, A. C., Spreafico, A., Pitts, T. M., Morelli, M. P., Selby, H. M., Kachaeva, M. I., Flanigan, S. A., Kulikowski, G. N., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0376 · Cited by 77 · cited 1×
“Upregulation of the noncanonical wingless/calcium signaling pathway (Wnt) signaling pathway is another mechanism by which KRAS mutated CRC cell lines showed resistance to selumetinib [24].”
BackgroundPitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., Leong, S., Coldren, C. D., Hirsch, F. R., Varella-Garcia, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3191 · Cited by 69 · cited 1×
“Previous experimentation with OSI-906, an (IGF1R)/insulin receptor (IR) tyrosine kinase inhibitor (TKI), revealed resistance to OSI-906 that was coupled with simultaneous activation of the MAPK pathway in CRC cell lines [50].”
BackgroundSpreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3140 · Cited by 68 · cited 2×
“Concomitant use of selumetinib and cyclosporine, inhibited tumor growth and caused tumor regression in patient derived tumor xenografts [32].”
BackgroundOvercoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0145 · Cited by 57
Li, C., Cui, J., Chen, M., Liu, C., Liu, F., Qian-de, Z., Zou, J., & Lu, P. (2015) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972274 · Cited by 56 · cited 1×
“reported on the preclinical efficacy of INK-128, a novel ATP-competitive inhibitor of mTORC1 and mTORC2 [38].”
BackgroundPitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113037 · Cited by 54 · cited 2×
“Similarly, Pitt et al. demonstrated synergistic anti-proliferative activity with the combination of PI3K/mTOR inhibitor PF-502 and the MEK1/2 inhibitor PD-901 [45].”
BackgroundA Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040
Wangab, Y., Van Becelaere, K., Jiang, P., Przybranowski, S., Omer, C., & Sebolt-Leopold, J. (2005) · Neoplasia · doi:10.1593/neo.04532 · Cited by 53 · cited 1×
“Amplification of the driving oncogene KRAS(13D) has been shown to drive acquired resistance to MEK1/2 inhibitors by increasing signaling through the ERK1/2 pathway [22,23].”
BackgroundAntitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
Blaser, B., Waselle, L., Dormond-Meuwly, A., Dufour, M., Roulin, D., Demartines, N., & Dormond, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-86 · Cited by 48 · cited 2×
“demonstrated that PP242, an ATP competitive inhibitor of mTORC1 and mTORC2, reduced the growth, proliferation and survival of colon cells more efficiently than rapamycin [36].”
BackgroundRoper, J., Sinnamon, M. J., Coffee, E. M., Belmont, P. J., Keung, L., Richard, L. G., Wang, W. V., Faber, A. C., Yun, J., Yilmaz, Ö. H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.018 · Cited by 44
Zhang, Y.-J., Tian, X.-Q., Sun, D.-F., Zhao, S.-L., Xiong, H., & Fang, J.-Y. (2009) · Cancer Investigation · doi:10.1080/07357900802314893 · Cited by 42
Wilky, B. A., Rudek, M. A., Ahmed, S. R., Laheru, D. A., Cosgrove, D., Donehower, R. C., Nelkin, B. D., Ball, D. W., Doyle, L. A., Chen, H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.515 · Cited by 39 · cited 1×
“responses [53].”
Cui, D., Cao, D., Yang, Y., Qiu, M., Huang, Y., & Cheng, Y. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2974-8 · Cited by 38 · cited 1×
“Thus, MEK has become a potential target for therapy given that mutation in these kinases has been identified as a negative predictor of benefit from EGFR inhibitor therapy [19–21].”
BackgroundE, J., Xing, J., Gong, H., He, J., & Zhang, W. (2015) · Tumor Biology · doi:10.1007/s13277-014-2667-5 · Cited by 29
Sequencing of treatment in metastatic colorectal cancer: Where to fit the target
Temraz, S. N., Mukherji, D., & Shamseddine, A. I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1993 · Cited by 27 · cited 1×
“for use in patients refractory to these therapies in the third-line [16].”
BackgroundSelf-citationJin, M., Petronella, B. A., Cooke, A., Kadalbajoo, M., Siu, K., Kleinberg, A., May, E. W., Gokhale, P. C., Schulz, R., Kahler, J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400160a · Cited by 21 · cited 1×
“IGF-1R is a key regulator of both PI3K and MAPK pathways; however, trials of single agent inhibitors of IGF-1R have shown only modest clinical responses [49].”
BackgroundLi, W., Shi, Q., Wang, W., Liu, J., Ren, J., Li, Q., & Hou, F. (2014) · Colorectal Disease · doi:10.1111/codi.12749 · Cited by 12
Cited by
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
“Mutation of the p53 gene or deletion of the 17p chromosome is significant for tumor initiation, especially from adenoma to carcinoma in CRC [157,158]. p53 inhibits mTOR activity via AMPK-β1 and TSC2 in CRC cell lines. p53 also regulates the mTOR pathway by a target gene, DNA damage and development 1 (REDD1), which is…”
BackgroundInfluentialSepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9807 · Cited by 360
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
“Combinations of agents targeting distinct RAS effector pathways are currently under clinical investigation, and it remains to be seen whether these combinations will be tolerated at doses that may provide therapeutic benefit (10, 11).”
BackgroundSepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
The current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171
Metadata
- Authors
- Temraz, S., Mukherji, D., & Shamseddine, A.
- Affiliations
- American University of Beirut Medical Center (LB)
- Corresponding author
- Temraz, Sally
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-09-23
- Volume
- 16
- Issue
- 9
- Pages
- 22976-22988
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4613347
- OpenAlex
- W2120687938
- Cited by
- 117
- References
- 55
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 2 · 2021: 9 · 2020: 13 · 2019: 15 · 2018: 19 · 2017: 16 · 2016: 10
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- colorectal cancer, MEK inhibitors, PI3K signaling, KRAS mutation, BRAF mutation, MAPK signaling, PI3K/mTOR inhibitors, drug resistance, Wnt signaling, PIK3CA, Akt, IGF-1 receptor, combination therapy
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Colon, Humans, Mutation, Rectum, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.